CNS Pharmaceuticals Licenses DNA-Binding Agent from MD Anderson, Doubling its Drug Pipeline

HOUSTON, Jan. 13, 2020 -- (Healthcare Sales & Marketing Network) -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced it has ent... Biopharmaceuticals, Oncology, Licensing CNS Pharmaceuticals, WP1244, blood-brain barrier
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news